The goal of these investigations is to develop and use genetically engineered murine tumor cells for the treatment of established metastases. The rationale for these studies is based on the hypothesis that tumor cells express """"""""hapten-like"""""""" antigens that are poorly immunogenic but remain antigenic in that they can be recognized by an engendered immune response. The transfection and expression of a strong viral antigen such as hemagglutinin (HA) provides a basis for """"""""associative recognition"""""""", where a response to HA fosters a response to the tumor associated antigen (TAA). This point has been proven using three different murine tumors which when transfected with, and expressing HA, protect against a challenge with non- transfected parent cells. A second goal of these studies is to transfect murine tumors with genes coding for lymphokines such as IL_2 and IL-4, or IFN-gamma. These new cell lines will allow us to address the role of delayed type hypersensitivity (65kDa) and MHC Class I expression (IFN- gamma), in tumor rejection. They will also allow us to determine more conclusively if bypassing T-cell help accelerates the immune response (IL- 4). Our ultimate goal is to use these genetically engineered cells, or combinations thereof, to treat established metastases in mice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA041525-07
Application #
3182108
Study Section
Pathology B Study Section (PTHB)
Project Start
1986-08-01
Project End
1995-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
7
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Huang, S; Xie, K; Bucana, C D et al. (1996) Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 2:1969-79
Jean, D; Bar-Eli, M; Huang, S et al. (1996) A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res 56:254-8
Hudson, J M; Frade, R; Bar-Eli, M (1995) Wild-type p53 regulates its own transcription in a cell-type specific manner. DNA Cell Biol 14:759-66
Huang, S; Xie, K; Singh, R K et al. (1995) Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J Interferon Cytokine Res 15:655-65
Luca, M; Xie, S; Gutman, M et al. (1995) Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene 11:1399-402
Singh, R K; Gutman, M; Reich, R et al. (1995) Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res 55:3669-74
Radinsky, R; Fidler, I J; Price, J E et al. (1994) Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene 9:1877-83
Huang, S; Singh, R K; Xie, K et al. (1994) Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 39:231-8
Gutman, M; Singh, R K; Radinsky, R et al. (1994) Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res 14:1759-65
Ellerhorst, J A; Frost, P; Abbruzzese, J L et al. (1993) 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer 67:209-15

Showing the most recent 10 out of 22 publications